Rudy Li

Wolfe Research

Rudy Li is an analyst from Wolfe Research Ranked #75 out of 4746 analysts, they have issued 26 stock ratings with a success rate of 97.67% and an average return of 94.65%.

Rudy Li has a well-established track record, with 26 ratings issued in the market sector. They have consistently delivered a success rate of 97.67% and an average return of 94.65%, underscoring their expertise and ability to identify winning opportunities for investors.

#75

Out of 4746

26

Total Ratings

+97.67%

Success Rate

+94.65%

Average Return

Recent Ratings Analysis

QURE

Jul 30, 2026

Target

$65.00

Current

$40.07

Performance

—

Rudy Li rated QURE as Outperform on Jul 30, 2026, setting a price target of 65. Shares have remained stable near 40.07, leaving the 65 target still in play.

LBRX

Jul 07, 2026

Target

$45.00

Current

$39.00

Performance

13.74%

On Jul 07, 2026, LBRX was given a Outperform rating by Rudy Li, with a target price of 45. The stock rallied 13.74% after the rating, narrowing the gap to the target of 45 and validating the bullish stance.

CNTA

Feb 24, 2026

Target

$40.00

Current

$40.50

Performance

52.71%

CNTA received a Outperform rating from Rudy Li on Feb 24, 2026, aiming for 40. Momentum has favored the Buy call, with shares climbing from 40.5 to 40.5, rewarding those who trusted the recommendation.

DFTX

Feb 24, 2026

Target

$25.00

Current

$42.16

Performance

141.60%

On Feb 24, 2026, Rudy Li published a Outperform outlook on DFTX, with a target of 25. Shares gained 141.60%, underscoring the accuracy of the bullish outlook toward 25.

DNLI

Feb 24, 2026

Target

—

Current

$23.85

Performance

11.29%

Rudy Li on Feb 24, 2026 assigned DNLI a Peer Perform rating, with a price target of null. Shares outperformed expectations, climbing 11.29% despite the neutral view.

NBIX

Feb 24, 2026

Target

$160.00

Current

$180.79

Performance

38.05%

On Feb 24, 2026, Rudy Li reaffirmed NBIX with a Outperform rating, targeting 160. The recommendation was supported by strong follow-through as the stock rose from 180.79 to 180.79.

PRAX

Feb 24, 2026

Target

$500.00

Current

$291.03

Performance

-15.08%

PRAX was rated Outperform by Rudy Li on Feb 24, 2026, with a price objective of 500. This case shows how bullish projections can fail, with the stock now below 291.03.

STOK

Feb 24, 2026

Target

$40.00

Current

$29.48

Performance

-16.96%

On Feb 24, 2026, Rudy Li initiated coverage on STOK with a Outperform rating and target of 40. The Buy call has yet to be validated as shares remain 10.52 away from the target.

XENE

Feb 24, 2026

Target

$60.00

Current

$63.10

Performance

40.88%

Rudy Li issued a Outperform recommendation for XENE on Feb 24, 2026, price target set at 60. Investors following the Buy call captured upside momentum, with shares now at 63.1.

ACAD

Feb 24, 2026

Target

$33.00

Current

$26.34

Performance

7.12%

On Feb 24, 2026, ACAD was evaluated by Rudy Li, who gave a Outperform rating and target of 33. This case illustrates how a timely bullish rating can translate into tangible gains of 7.12%.

ALKS

Feb 24, 2026

Target

$45.00

Current

$48.34

Performance

44.77%

Rudy Li rated ALKS as Outperform on Feb 24, 2026, setting a price target of 45. The call has proven timely, with shares rising 44.77% toward the price target of 45.

AXSM

Feb 24, 2026

Target

$230.00

Current

$227.42

Performance

33.82%

On Feb 24, 2026, AXSM was given a Outperform rating by Rudy Li, with a target price of 230. The stock rallied 33.82% after the rating, narrowing the gap to the target of 230 and validating the bullish stance.

DRUG

Jan 02, 2026

Target

$80.00

Current

$71.06

Performance

-14.86%

DRUG received a Buy rating from Rudy Li on Jan 02, 2026, aiming for 80. The rating hasn’t played out as hoped, with the stock trading 14.86% below expectations.

IMUX

Sep 29, 2025

Target

$3.00

Current

$13.05

Performance

39.60%

On Sep 29, 2025, Rudy Li published a Buy outlook on IMUX, with a target of 3. Shares gained 39.60%, underscoring the accuracy of the bullish outlook toward 3.

RVPH

Sep 29, 2025

Target

$2.00

Current

$0.41

Performance

-93.35%

Rudy Li on Sep 29, 2025 assigned RVPH a Buy rating, with a price target of 2. The call has struggled to gain traction, with shares losing 93.35%.

ANRO

Sep 29, 2025

Target

$15.00

Current

$26.72

Performance

566.33%

On Sep 29, 2025, Rudy Li reaffirmed ANRO with a Buy rating, targeting 15. The recommendation was supported by strong follow-through as the stock rose from 26.72 to 26.72.

PRTA

Aug 28, 2025

Target

$18.00

Current

$8.56

Performance

3.88%

PRTA was rated Buy by Rudy Li on Aug 28, 2025, with a price objective of 18. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

MNMD

Aug 01, 2025

Target

$20.00

Current

$20.69

Performance

145.14%

On Aug 01, 2025, Rudy Li initiated coverage on MNMD with a Buy rating and target of 20. The stock’s climb of 145.14% since the call highlights the foresight in the rating.

Frequency Asked Questions

Who is Rudy Li?

Rudy Li is an analyst from Wolfe Research.

What is Rudy Li's success rate?

Rudy Li currently has a success rate of +97.67%.

How many ratings has Rudy Li issued?

Rudy Li has issued 26 stock ratings so far.

What is the average return of Rudy Li's calls?

Their stock ratings have generated an average return of +94.65%.

What is Rudy Li's ranking?

Rudy Li is ranked #75 out of 4746 analysts.

What types of ratings does Rudy Li give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Rudy Li?

You can follow Rudy Li by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Rudy Li?

Their latest rating was a Buy on QURE issued on 2026-07-30.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep